Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Arcturus Therapeutics

Arcturus Therapeutics

Arcturus Therapeutics is a lipid nanoparticle (LNP) siRNA drug delivery systems founded in 2013 by Pad (Padmanabh) Chivukula.

Specializing in RNA medicines, Arcturus Therapeutics focuses on diseases with high unmet needs.


Their central product is a proprietary technology known as "LUNAR"(Lipid-enabled and Unlocked

Nucleomonomer Agent modified RNA). "LUNAR" is a delivery system that consists of a combination of RNAs and gene editing tools.


Arcturus in collaboration with Duke-National University of Singapore is developing an RNA based prophylactic vaccine to prevent COVID19 coronavirus infection.

The LUNAR-COVID19 combines Arcturus' self-replicating RNA STARR™ Technology with their LUNAR® RNA medicine delivery technology to develop a prophylactic vaccine against SARS-CoV-19. The combination of these two technologies results in (1) a RNA vaccine that can be produced more rapidly than conventional adjuvanted protein based vaccines, (2) a dramatic reduction in the RNA dose required to elicit a protective immune response, and (3) an increase in the duration of antigen expression potentially yielding protective immunity from SARS-CoV-19 with a single dose.


October 21, 2013
Arcturus Therapeutics raises a $5,000,000 series A round.
June 7, 2013
Arcturus Therapeutics raises a $1,300,000 seed round.
April 2013
Arcturus Therapeutics raises a $580,000 seed round.
Arcturus Therapeutics was founded by Joseph E. Payne and Pad (Padmanabh) Chivukula.

Funding Rounds


Further Resources



Emily Graffeo
December 29, 2020
The Singapore Health Sciences Authority approved the Arcturus vaccine candidate for Phase 2 clinical studies, though Wall Street was disappointed the medical company's latest vaccine update.
November 9, 2020
Arcturus Therapeutics Announces Positive Interim ARCT-021 (LUNAR-COV19) Phase 1/2 Study Results for Both Single Shot and Prime-boost Regimens, and Up to $220 Million in Additional Financial Commitments from Singapore - read this article along with other careers information, tips and advice on BioSpace
Martin Farrer
August 21, 2020
the Guardian
Travellers wear protective gear agianst the threat of coronavirus as they arrive in Los Angeles from New York. Photograph: Ringo Chiu/ZUMA Wire/REX/Shutterstock
June 5, 2020
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today announced that it has dosed the first healthy volunteer in a Phase 1 study with ARCT-810, the Company's messenger RNA (mRNA)-based therapeutic candidate for Ornithine Transcarbamylase (OTC) deficiency.


Golden logo
By using this site, you agree to our Terms & Conditions.